Dongwha Pharm Co., Ltd. (000020) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dongwha Pharm Co., Ltd. (000020:KRX), powered by AI.

Current Price
₩5,330
P/E Ratio
17.1
Market Cap
148.9B
Sector
Healthcare
What is the Dongwha Pharm Co., Ltd. stock price forecast?

Dongwha Pharm Co., Ltd. is currently trading at ₩5,330. View real-time AI analysis on Alpha Lenz.

What is Dongwha Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Dongwha Pharm Co., Ltd. on Alpha Lenz.

What is Dongwha Pharm Co., Ltd.'s P/E ratio?

Dongwha Pharm Co., Ltd.'s P/E ratio is 17.1.

Dongwha Pharm Co., Ltd.

KRX · 000020
₩5,330-40(-0.74%)Market closedKRX regular session 09:00–15:30 KST
Ask about Dongwha Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Dongwha Pharm Co., Ltd. trades at a P/E of 17.1 (fair value) with modest ROE of 2.3%. 3Y revenue CAGR of 13.4% highlights clear growth momentum.

Ask for details

Company Overview

Dongwha Pharm Co., Ltd. is a pharmaceutical company primarily engaged in the research, development, manufacturing, and marketing of medicinal products. Established in South Korea, the company has a rich history and is known for its contributions to the healthcare industry. Dongwha Pharm's product portfolio includes over-the-counter drugs, prescription medications, health supplements, and healthcare products. The company operates within both domestic and international markets, offering a broad range of pharmaceuticals that cater to diverse medical needs. Dongwha Pharm Co., Ltd. places a strong emphasis on innovation and quality, investing significantly in research and development to ensure the effectiveness and safety of its products. It serves a wide array of therapeutic areas including cardiovascular, gastrointestinal, and respiratory health, among others. As a key player in the South Korean pharmaceutical industry, Dongwha Pharm contributes to public health advancements and economic vitality through its expansive product line and commitment to scientific research. The company actively participates in the global pharmaceutical supply chain, maintaining partnerships and collaborations that enhance its competitive position in the market.

CEO유준하, 윤인호(각자 대표이사)
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees825

Company Statistics

FY 2025

Profile

₩148,874,735,100Market Cap
₩496,394,309,770Revenue
27.93MShares Out
825Employees

Margins

44.03%Gross
4.96%EBITDA
0.05%Operating
1.21%Pre-Tax
0.77%Net

Valuation

17.14P/E
0.39P/B
0.30EV/Sales
11.21EV/EBITDA
-3.76P/FCF

Growth (CAGR)

13.40%Rev 3Yr
12.78%Rev 5Yr
-79.53%Op Inc 3Yr
-59.36%Op Inc 5Yr
-43.75%Net Inc 3Yr
-33.12%Net Inc 5Yr

Returns

0.61%ROA
2.31%ROE
1.67%ROIC

Financial Health

₩13,305,439,070Cash & Cash Equivalents
₩227,422,995,950Net Debt
59.97%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Dongwha Pharm Co., Ltd. (ticker: 000020) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 825 employees. Market cap is $148.9B.

The current price is ₩5,330 with a P/E ratio of 17.14x and P/B of 0.39x.

ROE is 2.31% and operating margin is 0.05%. Annual revenue is $496.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Dongwha Pharm Co., Ltd. (000020) Stock Forecast 2026 ₩5,330 — Price, Financials & Analyst Targets | Alpha Lenz